Abaxis (Nasdaq: ABAX ) is expected to report Q4 earnings on April 25. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Abaxis's revenues will grow 22.8% and EPS will grow 23.8%.
The average estimate for revenue is $52.5 million. On the bottom line, the average EPS estimate is $0.26.
Last quarter, Abaxis tallied revenue of $49.8 million. GAAP reported sales were 32% higher than the prior-year quarter's $37.9 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, EPS came in at $0.22. GAAP EPS of $0.22 for Q3 were 69% higher than the prior-year quarter's $0.13 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 52.4%, 170 basis points worse than the prior-year quarter. Operating margin was 15.4%, 310 basis points better than the prior-year quarter. Net margin was 10.0%, 250 basis points better than the prior-year quarter.
The full year's average estimate for revenue is $188.5 million. The average EPS estimate is $0.79.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 163 members out of 179 rating the stock outperform, and 16 members rating it underperform. Among 41 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 37 give Abaxis a green thumbs-up, and four give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Abaxis is outperform, with an average price target of $41.28.
Is Abaxis the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
- Add Abaxis to My Watchlist.